![Thermalin diabetes, llc](/api/images/company-pic/0-562979-company.jpg)
Bize Ulaşın
Şirket hakkında
Thermalin hopes to disrupt the $30B insulin/insulin delivery market with a disposable, postage-stamp-sized glucose management system enabled by our first-in-class stabilized, highly concentrated, and ultra-rapid acting insulin. This same new insulin molecule in "ordinary" (U-100) concentration will enable the factory-filling of reservoirs for existing insulin pumps. In addition to this lead program, Thermalin is developing partnerships on no-cold-chain basal and mix insulins and on glucose-responsive insulins.
US
Bilinmeyen
Doğrulanmamış şirket
iş şeffaflığı
- Şirket bilgileri doğrulanmadı
- Müşterilerinden inceleme isteyin
- Olumsuz yorumlara cevap vermedi